title: Galangin dampens mice lipopolysaccharide-induced acute lung injury.
abstract: Galangin, an active ingredient of Alpinia galangal, has been shown to possess anti-inflammatory and antioxidant activities. Inflammation and oxidative stress are known to play vital effect in the pathogenesis of acute lung injury (ALI). In this study, we determined whether galangin exerts lung protection in lipopolysaccharide (LPS)-induced ALI. Male BALB/c mice were randomized to receive galangin or vehicle intraperitoneal injection 3 h after LPS challenge. Samples were harvested 24 h post LPS administration. Galangin administration decreased biochemical parameters of oxidative stress and inflammation, and improved oxygenation and lung edema in a dose-dependent manner. These protective effects of galangin were associated with inhibition of nuclear factor (NF)-κB and upregulation of heme oxygenase (HO)-1. Galangin reduces LPS-induced ALI by inhibition of inflammation and oxidative stress.
authors.affiliation: Department of Thoracic Surgery, Subei People's Hospital of Jiangsu Province, Yangzhou, 225001, Jiangsu, People's Republic of China, augming@yahoo.com.
authors.forename: Yu-Sheng
authors.initials: YS
authors.lastname: Shu
authors.forename: Wei
authors.initials: W
authors.lastname: Tao
authors.forename: Qian-Bing
authors.initials: QB
authors.lastname: Miao
authors.forename: Shi-Chun
authors.initials: SC
authors.lastname: Lu
authors.forename: Ya-Bing
authors.initials: YB
authors.lastname: Zhu
mesh_terms: D055371:Acute Lung Injury / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control*; D000818:Animals; D005419:Flavonoids / Q000494:pharmacology / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000633:toxicity*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*
chemical_list: D005419:Flavonoids; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; C037032:galangin
references.citation: Eur J Pharmacol. 2012 Feb 29;677(1-3):1-4
references.pmid: 22200625
references.citation: Food Chem. 2012 Dec 15;135(4):2702-7
references.pmid: 22980861
references.citation: Shock. 2002 Sep;18(3):236-41
references.pmid: 12353924
references.citation: Mol Med. 2011 Mar-Apr;17(3-4):293-307
references.pmid: 21046059
references.citation: Respir Res. 2012 Dec 02;13:110
references.pmid: 23199346
references.citation: Eur J Pharmacol. 2013 Jan 5;698(1-3):57-66
references.pmid: 22985747
references.citation: Molecules. 2012 Nov 09;17(11):13403-23
references.pmid: 23143152
references.citation: Am J Respir Cell Mol Biol. 2013 Mar;48(3):271-9
references.pmid: 23087053
references.citation: Am J Respir Med. 2003;2(3):211-9
references.pmid: 14720003
references.citation: Toxicol Appl Pharmacol. 2013 Oct 15;272(2):408-13
references.pmid: 23800689
references.citation: Evid Based Complement Alternat Med. 2013;2013:767689
references.pmid: 23762160
references.citation: Pulm Pharmacol Ther. 2012 Feb;25(1):99-103
references.pmid: 22210005
references.citation: Evid Based Complement Alternat Med. 2013;2013:590363
references.pmid: 23573137
references.citation: Inflammation. 2012 Feb;35(1):150-7
references.pmid: 21302135
references.citation: Evid Based Complement Alternat Med. 2013;2013:127672
references.pmid: 23401705
references.citation: Mol Med Rep. 2012 Aug;6(2):297-302
references.pmid: 22641469